20% Off Everything · No Code NeededThird-Party Tested at the Source LabShips Within 1 Business Day · TrackedU.S. Sourced · U.S. ShippedFree 2-Day Shipping at $1,000 and Over≥99% Purity — HPLC + Mass SpecLot-Matched Certificate on File for Every Lot We Ship20% Off Everything · No Code NeededThird-Party Tested at the Source LabShips Within 1 Business Day · TrackedU.S. Sourced · U.S. ShippedFree 2-Day Shipping at $1,000 and Over≥99% Purity — HPLC + Mass SpecLot-Matched Certificate on File for Every Lot We Ship
For Laboratory & Research Use Only — Not for Human or Veterinary Use
All ProductsGLP-1 & MetabolicResearch PeptidesPeptide BlendsNasal SpraysDissolving StripsBioregulatorsResearch BundlesLab Supplies Search

CJC-1295 Adverse Events in the Literature: Water Retention, Flushing, Cortisol and Prolactin Findings, DAC vs No DAC

CJC-1295 Adverse Events in the Literature: Water Retention, Flushing, Cortisol and Prolactin Findings, DAC vs No DAC

The adverse events reported for CJC-1295 come almost entirely from one published human trial, and that trial studied CJC-1295 with DAC, the long-acting, albumin-bound form, not the No DAC backbone sold in most research combination vials. In that trial, the most consistently recorded events were injection-site reactions; the authors' tolerability summary did not describe clinically meaningful changes in cortisol or prolactin at the amounts tested. No dedicated published human adverse-event dataset for CJC-1295 No DAC, administered on its own, was identified for this article.

QuestionWhat the published record showsSource
Which CJC-1295 form has published human adverse-event data?CJC-1295 with DAC only, from one Phase 1 trial in healthy adultsTeichman et al., 2006, PubMed 16352683
What was the most frequently recorded event category?Injection-site reactions, described as mild and transient in the trial's tolerability summaryTeichman et al., 2006
Did the trial report a cortisol change?No clinically significant cortisol change described at the amounts testedTeichman et al., 2006
Did the trial report a prolactin change?No clinically significant prolactin change described at the amounts testedTeichman et al., 2006
Is there published adverse-event data for CJC-1295 No DAC alone?Not identified; the No DAC backbone pharmacologically resembles the shorter-acting GHRH(1-29) analog classContrast drawn from Teichman et al., 2006 and Khorram et al., 1997, PubMed 9141536

What adverse events did the CJC-1295 trial record?

Teichman and colleagues ran a randomized, double-blind, placebo-controlled Phase 1 study of CJC-1295 with DAC in healthy adults, first across single ascending amounts and then across a repeated-injection arm lasting about a month. The trial's published tolerability summary describes the compound as generally well tolerated across both parts of the study, with injection-site findings, mild and transient erythema or local discomfort at the injection site, as the event category recorded most often. Systemic events beyond the injection site were reported as infrequent and not clearly amount-related in the published summary. Readers who need the exact per-cohort event counts and severity grading should go to the primary trial report rather than this summary, since a secondary description cannot substitute for the trial's own adverse-event tables.

What did the trial report for cortisol and prolactin specifically?

Cortisol and prolactin matter here because several older growth hormone-releasing peptides are known to raise one or both at the amounts needed for a full GH response, a pattern that has shaped how newer GH-axis secretagogues are evaluated. Because CJC-1295 acts on the GHRH receptor rather than on the ghrelin receptor or other pathways associated with adrenal and lactotroph activation, the trial's published summary does not describe a clinically significant rise in either cortisol or prolactin at the amounts tested. This is consistent with the receptor-selectivity logic described for ipamorelin by Raun and colleagues, even though ipamorelin and CJC-1295 act on different receptors and were not tested in the same study; both papers report that their respective GHRH-receptor or ghrelin-receptor mechanism did not meaningfully move the adrenal and lactotroph hormones measured alongside GH.

Where does "water retention" fit into the CJC-1295 literature?

Fluid retention and joint discomfort are reported as class-level findings in the broader recombinant growth hormone replacement literature, where sustained elevation of GH and IGF-1 over weeks to months has been associated with these events in adults. The CJC-1295 trial itself, run over a shorter period with intermittent rather than continuous GH-axis elevation, does not describe a distinct water-retention finding in its own published tolerability summary; the association with fluid retention in search results is better understood as background context from the GH-replacement literature than as a finding specific to the CJC-1295 trial. Anyone evaluating this question for a longer or higher-amount research design should treat fluid balance as a parameter worth tracking precisely because of that broader GH-axis literature, not because the CJC-1295 trial itself reported it.

Why does DAC vs No DAC change what adverse-event data exists?

The DAC linkage, first described by Jette and colleagues in rats as a covalent albumin conjugate that kept the GHRH analog in circulation far longer than the unconjugated peptide, is what gives CJC-1295 its multi-day clearance. That same property is what made a human Phase 1 tolerability study worth running: a molecule with a GH/IGF-1 effect lasting days justifies closer safety monitoring across a longer window than a molecule cleared in minutes. The No DAC backbone, lacking that albumin-binding chemistry, behaves pharmacologically more like a short-acting GHRH(1-29) analog, the same general class as sermorelin and the long-term GHRH(1-29) analog studied by Khorram and colleagues in older adults. That trial's own tolerability findings, reported across a full year of twice-daily subcutaneous administration, also centered on injection-related, local events rather than systemic findings, which is a useful reference point for the general tolerability profile of unmodified GHRH(1-29)-class peptides, though it was not run on the specific No DAC product sold in combination vials and should not be read as that product's own dataset. The structural basis for this distinction is covered in more detail at cjc-1295-dac-vs-no-dac. The Sermorelin page summarises that GHRH(1-29) record, including what the Khorram study reported for growth hormone and IGF-1.

How was safety monitored in the CJC-1295 trial?

A Phase 1 study of this kind is built around safety monitoring as much as around the hormone endpoints, and the published description of the Teichman trial reflects that structure. Subjects were observed in a controlled unit setting around the time of each injection, with vital signs, injection-site assessment and blood sampling for clinical chemistry and hematology performed at prespecified intervals through the single-amount phase and again through the month-long repeated-injection phase. Clinical chemistry panels of this type routinely include liver enzymes, renal markers, electrolytes, glucose and the hormone panel already discussed (GH, IGF-1, cortisol, prolactin), which is why a tolerability summary from a trial like this can speak to more than just injection-site findings even when those findings dominate the published narrative. The repeated-injection phase is the more informative of the two for a research vial intended for anything beyond a single administration, since it is the only part of the published record that observed the compound across a dosing interval measured in weeks rather than hours.

Does a secondary safety review add anything beyond the trial's own tolerability summary?

Sigalos and Pastuszak reviewed published safety and efficacy data across the growth hormone secretagogue class, including GHRH analogs and ghrelin-receptor agonists, and summarized the pattern seen across multiple studies rather than reporting a new trial of their own. Read alongside the Teichman trial, that review places CJC-1295's injection-site-dominant tolerability profile within a broader class pattern: GH secretagogues as a group are reported more often for local injection findings than for systemic events, and class-level cortisol or prolactin changes are generally tied to older ghrelin-receptor agonists rather than to GHRH-receptor agonists like CJC-1295. A secondary review of this kind is useful for context but does not substitute for the per-study event tables in the primary trial reports.

Did the GHRH-knockout mouse study report any observations relevant to tolerability?

Alba and colleagues administered CJC-1295 once daily to mice lacking a functional GHRH receptor, a design built to confirm mechanism rather than to generate a human-relevant safety dataset. The paper's focus was on whether GH secretion was restored, not on cataloguing adverse events, so it adds mechanistic support for why CJC-1295 depends on the GHRH receptor rather than direct tolerability data of the kind the Teichman trial provides.

What was reported: the adverse events, as printed, by study

StudyModel and nAmount and route as reportedEndpointFinding (adverse events / tolerability)
Teichman et al., 2006, PubMed 16352683Healthy adult volunteers, single-amount cohorts, placebo-controlledSingle subcutaneous injection, amount escalated across separate cohortsAdverse events, injection-site findings, clinical chemistry including cortisol and prolactinGenerally well tolerated; injection-site reactions were the most frequently recorded event; no clinically significant cortisol or prolactin change described
Teichman et al., 2006Healthy adult volunteers, repeated-injection cohorts over about a monthSubcutaneous injections repeated on a once- or twice-weekly intervalAdverse events and tolerability across repeated administrationNo new event categories reported beyond the single-amount phase; described as well tolerated across the repeated-injection period
Khorram et al., 1997, PubMed 9141536Age-advanced men and women, human trial, twice-daily subcutaneous administration for one yearTwice-daily subcutaneous injection of a GHRH(1-29) analog for a one-year study periodTolerability over a one-year chronic-dosing designReported as consistent with the injection-related, local-reaction pattern typical of this peptide class over chronic administration
Raun et al., 1998, PubMed 9849822Rats and pigs (in vivo), ipamorelin for mechanistic comparisonInjection across a series of amounts reported in the paperCortisol, ACTH, prolactin, aldosterone alongside GHNo meaningful change in the four comparison hormones at amounts producing a maximal GH response, supporting the selectivity contrast discussed above
Jette et al., 2005Rats (in vivo), albumin-conjugate pharmacologyInjection of the albumin-bound GRF(1-29) conjugate at amounts reported in the paperPituitary receptor activation, plasma persistence of the conjugateNo adverse findings were the focus of this mechanism paper; it establishes the DAC chemistry that later made a dedicated human tolerability study necessary
Alba et al., 2006Mice with a non-functional GHRH receptor (genetic model)Once-daily subcutaneous injection of CJC-1295 at the amount reported in the paperGH secretory patternGH secretion was restored; the paper's focus was mechanism confirmation rather than cataloguing adverse events

How is this handled in a research setting?

Because the published tolerability data exists only for CJC-1295 with DAC and not for the No DAC backbone used in most research vials, a bench record should track which form was used alongside any observation made during an assay, rather than assuming the Teichman trial's tolerability summary transfers directly to a No DAC preparation. Reconstitution and handling of lyophilized CJC-1295 preparations is covered at reconstituting-lyophilized-peptides, and confirming identity before attributing any observed effect to the peptide itself, rather than to a degraded or misidentified sample, is covered at how-to-read-a-peptide-coa. Lot-matched CJC-1295 (No DAC) plus ipamorelin and CJC-1295 (No DAC) plus GHRP-6 research vials ship with certificates that support this kind of record-keeping.

Frequently asked questions

What was the most common event recorded in the CJC-1295 trial?

Injection-site reactions, described in the trial's published tolerability summary as mild and transient.

Did the CJC-1295 trial report flushing as an event?

Flushing is reported for several growth hormone-releasing peptides and secretagogues as a class, often linked to the speed of hormone release or to the injection itself; the Teichman trial's own published summary centers on injection-site findings rather than a specific flushing event, and the exact event list should be confirmed against the primary source for any formal comparison.

Does CJC-1295 raise cortisol the way some older GH secretagogues do?

The published trial's tolerability summary does not describe a clinically significant cortisol change at the amounts tested, consistent with its GHRH-receptor mechanism rather than pathways more associated with adrenal activation in other secretagogue classes.

Is there separate adverse-event data for CJC-1295 No DAC?

Not a dedicated published dataset identified for this article. Its pharmacological similarity to the GHRH(1-29) analog class, including the peptide studied by Khorram and colleagues, is the closest available reference point, discussed further at cjc-1295-dac-vs-no-dac.

Were any systemic adverse events reported beyond the injection site?

The published tolerability summary describes systemic events as infrequent in both the single-amount and repeated-injection parts of the trial; specific event terms and counts should be read from the primary source.

How does CJC-1295's reported tolerability compare with ipamorelin's selectivity data?

Both papers report that their respective mechanism did not meaningfully move cortisol, ACTH or prolactin at amounts producing a GH response, though the two were studied separately and the comparison is mechanistic rather than from a shared trial. A mechanism-level comparison of pairing the two is at cjc-1295-and-ipamorelin-in-combination-research.

Were liver, kidney or blood sugar markers affected in the trial, and does the repeated-injection phase add information beyond the single-amount phase?

The trial's clinical chemistry panel, which in studies of this design routinely covers liver enzymes, renal markers and glucose alongside the hormone measurements, was reported as part of the overall tolerability picture; the published summary does not describe a clinically significant abnormality attributed to CJC-1295 in these parameters at the amounts tested. The repeated-injection phase is the more informative of the two for a multi-week research design, since it is the only part of the published trial that observed subjects across a dosing interval measured in weeks rather than hours; researchers planning their own chemistry panel should design it around the full list in the primary source rather than this summary.

References

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed PMID 16352683.
  2. Khorram O, Laughlin GA, Yen SSC. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PubMed PMID 9141536.
  3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed PMID 9849822.
  4. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PubMed PMID 10373343.
  5. Jette L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PubMed PMID.
  6. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PubMed PMID.
  7. Alba M, Fintini D, Sagazio A, Hill CM, Rouque M, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth hormone secretion in mice with a targeted deletion of the GHRH receptor. J Clin Endocrinol Metab. 2006. PubMed PMID.

Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.

← Back to the blog